<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372934">
  <stage>Registered</stage>
  <submitdate>15/05/2017</submitdate>
  <approvaldate>16/06/2017</approvaldate>
  <actrnumber>ACTRN12617000881336</actrnumber>
  <trial_identification>
    <studytitle>Effects of 3 different phosphate binders on the formation of calciprotein particles in participants receiving haemodialysis treatment</studytitle>
    <scientifictitle>Sevelamer vs Calcium to Reduce Fetuin A calciprotein particles in dialysis (SCaRF) study</scientifictitle>
    <utrn />
    <trialacronym>SCaRF</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Calcium carbonate (oral (600mg tablets), up to 3 tablets three times a day) treatment for 12 weeks followed by randomisation to either :
Calcium Carbonate, oral (800 mg tablets), up to 3 tablets three times a day
Sevelamer Hydrochloride, oral (800 mg tablets), up to 3 tablets three times a day
Sevelamer Carbonate, oral, up to 3 tablets three times a day
for a period of 24 weeks.  
Starting dose when changing from calcium carbonate to either Sevelamer carbonate or Sevelamer hydrochloride is based  on the number of tablets taken, 1 tablet of calcium carbonate is considered to be equivalent to 1 tablet of Sevelamer carbonate/hydrochloride in terms of binding phosphate in the gastrointestinal tract. Participants will commence the new medication taking the same number of tablets daily as they were on previously.  Dosing is dependent participant's serum phosphate level and is targeted to a serum phosphate &lt;2.0 mmol/L. Phosphate is monitored every 4 weeks in line with standard of care, study drug dose remains unchanged unless there is indication of hypo or hyper phophataemia.  If serum phosphate is &lt;0.8 mmol/L decrease dose by 1 tablet per day.  Participant is withdrawn if serum phosphate is &lt;0.8 m mol/L and not on  phosphate binder medication.  If serum phosphate is &lt;0.6 mmol/L then all phosphate binders should cease and level should be checked in 3 days. If serum phosphate is above 2.6 mmol/L on maximum dose of phosphate binder (Calcium carbonate &gt; 5.4 g/day (i.e. 9 X 600 mg tablets); Sevelamer HCL  &gt; 7.2 g/day (i.e. 9 X 800 mg tablets); Sevelamer carbonate &gt;7.2 g/day  (i.e. 9 X 800 mg tablets )then participant should be withdrawn from the study.
Compliance will be monitored by package returns.</interventions>
    <comparator>Comparisons will be made with all three groups</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Levels of fetuin A -  calciprotein particles in serum obtained from participants in each group</outcome>
      <timepoint>36 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in vascular stiffness as measured by central pulse wave velocity.</outcome>
      <timepoint>36 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients receiving haemodialysis treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Uncontrolled plasma phosphate (&gt;2.6 mmol/L)
Cinacalcet use
Patients likely to have a parathyroidectomy
Allergy or intolerance to sevelamer or calcium carbonate
Lower limb amputation
History of calciphylaxis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Computer based randomisation.  Allocation by central computer is concealed to person making allocation</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>2/03/2017</actualstartdate>
    <anticipatedenddate>1/12/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - City campus - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Melbourne Hospital</primarysponsorname>
    <primarysponsoraddress>Grattan Street, Parkville, VIC 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Sanofi Aventis</fundingname>
      <fundingaddress>38 Beach Road, Singapore, 189767</fundingaddress>
      <fundingcountry>Singapore</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to look at  the effect of 3 registered phosphate binder on serum calci-protein particle formation.  It is hypothesised that formation of these particles may link inflammation with vascular stiffening and calcification. In turn the class of phosphate binder used my impact the quantity of these particles produced.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/09/2015</ethicapprovaldate>
      <hrec>HREC/15/MH/261</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Stephen Holt</name>
      <address>Department of Nephrology, Royal Melbourne Hospital, Grattan Street, Parkville, Vic 3050</address>
      <phone>+61393427000</phone>
      <fax />
      <email>steve.holt@mh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Maria Farrell</name>
      <address>Department of Nephrology, Royal Melbourne Hospital, Grattan Street, Parkville, Vic 3050</address>
      <phone>+61393427077</phone>
      <fax />
      <email>maria.farrell@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Stephen Holt</name>
      <address>Department of Nephrology, Royal Melbourne Hospital, Grattan Street, Parkville, Vic 3050</address>
      <phone>+61393427000</phone>
      <fax />
      <email>steve.holt@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Maria Farrell</name>
      <address>Department of Nephrology, Royal Melbourne Hospital, Grattan Street, Parkville, Vic 3050</address>
      <phone>+61393427077</phone>
      <fax />
      <email>maria.farrell@mh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>